LakeShore Biopharma Co., Ltd
LSB · NASDAQ
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Market Cap | $2 | $6 | $9 | $18 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $2 | $6 | $9 | $18 |
| Revenue | $1 | $1 | $1 | $1 |
| % Growth | 7.2% | -16.6% | 36.6% | – |
| Gross Profit | $1 | $0 | $1 | $0 |
| % Margin | 82.5% | 79.5% | 77.7% | 75.9% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -7.9% | -64.3% | -11.2% | -13.4% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -16.3% | -75.6% | -21.2% | -47.1% |
| EPS Diluted | -0.94 | -4.05 | -1.88 | -0.019 |
| % Growth | 76.8% | -115.4% | -10,062.2% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |